SEATTLE — In the ARCHER trial, ANX007 did not meet the primary endpoint of mean rate of change in geographic atrophy lesion size compared with sham.
However, it demonstrated a novel neuroprotective mechanism of action across multiple visual function benefits.
“These were highly statistically significant for visual acuity endpoints and were dose and time dependent,” Jeffrey Heier, MD, said at the American Society of Retina Specialists annual meeting.
ANX007 (Annexon) is a Fab antibody fragment that selectively inhibits the complement component C1q. Heier said that C1q is a key